Dare Bioscience, Inc.
Summary
Dare Bioscience, Inc. filed a Form D on 2026-06-02, raising $65.0M in a private placement backed by Flagship Pioneering and ARCH Venture Partners. The first sale date was 2026-06-01, indicating the capital is already deployed. This is a significant raise for a private company in the Technology Venture sector.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
Dare Bioscience, Inc. filed a Form D on 2026-06-02, raising $65.0M in a private placement backed by Flagship Pioneering and ARCH Venture Partners. The first sale date was 2026-06-01, indicating the capital is already deployed. This is a significant raise for a private company in the Technology Venture sector.
Investor Edge
Watch for a subsequent Form D/A amendment, which would indicate additional capital or changed terms, signaling strong demand or a pivot in strategy. Also monitor for any public announcements from Dare Bioscience regarding partnerships or regulatory milestones.
Sector capital positioning
This $65M raise signals strong institutional appetite for high-risk, high-reward technology ventures, particularly those with ties to top-tier life science venture firms.
Convergence Signals
No direct public signals are evident from the filing data. However, the involvement of Flagship Pioneering and ARCH Venture Partners suggests potential connections to novel platform technologies or therapeutic assets that may have patent filings or upcoming clinical milestones.
Key Takeaways
- Dare Bioscience raised $65.0M in a private placement with first sale on 2026-06-01.
- Backed by elite venture firms Flagship Pioneering and ARCH Venture Partners.
- No public ticker; this is a private company filing a Regulation D notice.
Risk Indicators & Flags
No red flags in this initial Form D filing. The amount is large but consistent with the backing of top-tier VCs. No D/A amendments yet. Sector is Technology Venture, which is broad; specific risk depends on the company's actual product or service, which is not disclosed in the filing.
Verification & References
Filing is a Form D (initial notice) with SEC accession 000149315226026666. Verified via SEC EDGAR at https://www.sec.gov/cgi-bin/browse-edgar?company=DEFA14A%20-%20Dare%20Bioscience%2C%20Inc.%20(0001401914)%20(Filer)&type=D&action=getcompany. Amount raised is $65.0M. Related persons include Flagship Pioneering and ARCH Venture Partners.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Matthias Therapeutics, LLC
Uniform Bio Inc.
Anika Therapeutics, Inc.
DEF 14A - Outlook Therapeutics, Inc.
Strategy Inc
Outlook Therapeutics, Inc.
Pacira BioSciences, Inc.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Ushering in the Next Frontier of Quantum Innovation
This executive order updates the National Quantum Strategy and establishes a national effort (QC-ADDS) to develop a quantum computer for scientific discovery, with deployment at a Department of Energy facility. It directs multiple agencies to prioritize quantum sensing, networking, and supply chain initiatives, and mandates plans for commercial readiness and national security applications.
Securing the Nation Against Advanced Cryptographic Attacks
This executive order mandates a nationwide transition of federal information systems and critical infrastructure to post-quantum cryptography (PQC) by specific deadlines (2030 for key establishment, 2031 for digital signatures), directs NIST to lead technical guidance and a pilot project, requires agencies to appoint PQC migration leads, and orders the Federal Acquisition Regulatory Council to propose rules requiring contractors to comply with NIST PQC standards by 2030.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →